NX-5948 for Healthy Subjects
Trial Summary
What is the purpose of this trial?
This is a Phase 1, 2-part double-blinded (with respect to NX-5948/placebo), placebo-controlled study. Part 1 is a randomized, 3 period cross-over food-effect (FE) and drug-drug interaction (DDI) study. Part 2 is a single-period PK evaluation study.
Research Team
Sarah Injac, MD PhD
Principal Investigator
Nurix Therapeutics, Inc.
Eligibility Criteria
This trial is for healthy adults. Specific details about who can join are not provided, but typically participants should have no significant health issues and be willing to follow the study procedures.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Part 1: Food-Effect and Drug-Drug Interaction Study
Participants receive NX-5948 or placebo under fed and fasted conditions, and with fluconazole to evaluate food and drug-drug interactions.
Part 2: Pharmacokinetics Evaluation
Participants receive NX-5948 or placebo to assess pharmacokinetics following 2 doses given 12 hours apart.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- NX-5948
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nurix Therapeutics, Inc.
Lead Sponsor